Biocompatibility of Heparin‐Coated Extracorporeal Bypass Circuits: New Heparin Bonded Bioline System

Artificial Organs - Tập 24 Số 8 - Trang 618-623 - 2000
Eiki Tayama1, Nobuhiko Hayashida1, Koji Akasu1, Tomokazu Kosuga1, Shyuji Fukunaga1, Hidetoshi Akashi1, Takemi Kawara1, Shigeaki Aoyagi1
1Department of Surgery, Kurume University School of Medicine, Kurume, Japan.

Tóm tắt

Abstract: Biocompatibility of a new type of heparin‐coated cardiopulmonary bypass equipment, the Bioline, was evaluated in coronary artery bypass surgery cases. The heparin‐coated (H) group (n = 15; Quadrox Bioline oxygenator/reservior and Carmeda BioMedicus BP‐80 centrifugal pump) was compared with the nonheparin‐coated (N) group (n = 12; uncoated, otherwise similar oxygenator, centrifugal pump, tubing, and filter set). Both groups used full systemic heparinization. The peak values of neutrophil elastase, C3a, IL‐6, and IL‐8 at 2 h after cardiopulmonary bypass (CPB), and C3a levels at the end of CPB and at 2 h after CPB were significantly reduced in the H group compared with those of the N group. However, no statistically significant intergroup differences were observed in thrombin‐antithrombin complex, D‐dimer, β‐thromboglobulin, or platelet factor‐4. No significant differences were observed in hemostasis time, postoperative 12 h blood loss, required amount of blood transfusion, or intubation time. In conclusion, the Bioline demonstrated partially improved biocompatibility, in terms of leukocyte and complement activation, and proinflammatory cytokine production. However, it did not improve platelet activation, coagulation, or fibrinolysis cascade under full systemic heparinization. As a result, the clinical beneficial impact seemed to be the minimum.

Từ khóa


Tài liệu tham khảo

10.1016/0003-4975(91)91426-V

10.1016/0003-4975(93)90117-Z

10.1016/0003-4975(95)00777-i

10.1016/S0022-5223(95)70024-2

Bader KE, 1997, Biocompatibility in extracorporeal circulation: The heparin coating method Bioline Coating., Canadian Perfusion Canadienne, 9, 9

10.1016/0003-4975(93)91048-R

Kirklin JK, 1983, Complement and damaging effects of cardioplumonary bypass., J Thorac Cardiovasc Surg, 86, 845, 10.1016/S0022-5223(19)39061-0

10.1002/bjs.1800800106

10.1111/j.1540-8191.1993.tb00384.x

Steinberg JB, 1993, Cytokine and complement levels in patients undergoing cardiopulmonary bypass., J Thorac Cardiovasc Surg, 106, 1008, 10.1016/S0022-5223(19)33971-6

Kalfin RE, 1993, Induction of interleukin‐8 expression during cardiopulmonary bypass., Circulation, 88, 401

Hennein HA, 1994, Relationship of the proinflammatory cytokines to myocardial ischemia and dysfunction after uncomplicated revascularization., J Thoracic Cardiovasc Surg, 108, 626, 10.1016/S0022-5223(94)70286-1

10.1016/0003-4975(93)91143-B

10.1016/0003-4975(94)90736-6

Videm V, 1991, Biocompatibility of extracorporeal circulation., J Thorac Cardiovasc Surg, 101, 654, 10.1016/S0022-5223(19)36696-6

10.1016/0003-4975(96)00324-4

10.1016/S0022-5223(96)70395-1

Boonstra PW, 1994, Heparin coating of an extracorporeal circuit partly improves hemostasis after cardiopulmonary bypass., J Thorac Cardiovasc Surg, 107, 289, 10.1016/S0022-5223(94)70483-X

10.1016/S0022-5223(96)70275-1

Borowiec J, 1992, Heparin‐coated circuits reduce activation of granulocytes during cardiopulmonary bypass: A clinical study., J Thorac Cardiovasc Surg, 104, 642, 10.1016/S0022-5223(19)34730-0

10.1016/0003-4975(94)92231-4

10.1016/0003-4975(95)00366-s

10.1016/0003-4975(95)00763-6

Thông tin
Thông tin xuất bản

Artificial Organs

Tập 24 Số 8

618-623

Thông tin tác giả